Among patients with NSCLC, gastric cancer, or bladder cancer treated with nivolumab or pembrolizumab, sPD-1 levels were typically higher after the second cycle of treatment than at baseline, and a greater rate of increase between the second and fourth cycle of treatment correlated with an increase in tumor size [107]. This evidence concerns the gene HOXD13 and neoplasm.